Skip to content
Sexuality – Lifestyle
Author:
Sironax USA, Inc.
Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026
October 5, 2026
Sironax Announces Option Exercise and Asset Purchase
September 16, 2026
Sironax’s SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)
May 11, 2026
Sironax Announces Abstract on SARM1 Inhibitor SIR2501 Selected for Presentation at 2026 ASCO Annual Meeting
April 22, 2026